Chief Executive Officer
Dr C. Glenn Begley is a clinical haematologist and medical oncologist, whose academic and commercial roles include board level and senior positions in Australia, the USA and the UK. Most recently DrBegley was Chief Scientific Officer at Akriveia Therapeutics, a Californian biotech company focused on discovering and developing the next generation of cancer immunotherapies. He was also a non-Executive Director for UK-based Oxford BioTherapeutics.
His previous roles include:
- Chief Scientific Officer and Senior Vice-President, TetraLogic Pharmaceuticals (Pennsylvania)
- Vice-President and Global Head, Hematology and Oncology Research, Amgen (California)
- Executive Director, Western Australian Institute of Medical Research (Perth)
- Senior Principal Research Fellow and Professor of Medicine, Walter and Eliza Hall Institute of Medical Research, University of Melbourne
Dr Begley studied Medicine at undergraduate and postgraduate level at The University of Melbourne.
Chief Operating Officer
Linda Peterson is the Interim COO for BioCurate Pty Ltd, responsible for the set-up of the company and to ensure its operational arrangements are in place for the CEO and management team to commence business in 2017. Ms Peterson has extensive experience in the biomedical sector, leading and managing new initiatives, multidisciplinary teams and R&D projects. She is the Principal of her consulting business Linda Peterson and Associates and previous roles include the CEO of Bionic Enterprises Pty Ltd and Executive Manager of the Bionics Institute.
Linda’s qualifications include a Bachelor of Biological Sciences and post graduate qualifications in business administration.
Senior Project Leader
Dr Cathy Drinkwater has extensive experience in both academic research and industry drug development.
Following completion of her PhD at the Howard Florey Institute in Melbourne, Cathy went on to postdoctoral fellowships at Stanford University School of Medicine (California) and the Walter and Eliza Hall Institute of Medical Research (Melbourne). Since then she has worked in the commercial sector, as Principal Scientist at Amrad Corporation (later Zenyth Therapeutics) and Project Manager at CSL, and at the “interface”, with the Cancer Therapeutics CRC. During that time, she was responsible for a number of early discovery and development projects, working with research teams to enhance their collaborative efforts and facilitate the timely delivery of their outcomes.